Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Deffered Revenue (2016 - 2018)

Cardiff Oncology's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $1.1 million for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue fell 7.86% year-over-year to $1.1 million; the TTM value through Dec 2018 reached $1.1 million, down 7.86%, while the annual FY2018 figure was $1.1 million, 7.86% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $1.1 million at Cardiff Oncology, down from $1.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.4 million in Q3 2016 and bottomed at $1.0 million in Q2 2018.
  • The 3-year median for Non-Current Deffered Revenue is $1.2 million (2017), against an average of $1.2 million.
  • The largest annual shift saw Non-Current Deffered Revenue decreased 20.29% in 2017 before it grew 4.4% in 2018.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2016, then decreased by 13.83% to $1.2 million in 2017, then dropped by 7.86% to $1.1 million in 2018.
  • Per Business Quant, the three most recent readings for CRDF's Non-Current Deffered Revenue are $1.1 million (Q4 2018), $1.2 million (Q3 2018), and $1.0 million (Q2 2018).